Core Insights - Shanghai Weike Biotechnology Co., Ltd. has completed nearly 100 million RMB in Series A financing [1] - The financing round was led by Shenzhen Capital Group and followed by Xichuang Investment, with Fenghe Capital serving as the exclusive financial advisor [1] - The funds will accelerate the establishment of a cell and gene therapy (CGT) evaluation laboratory in the U.S., CGT evaluation services, clinical services, and the expansion of overseas biobreeding services [1]